O’Meara, Eileen

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 7,140

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 2,884

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiomyopathy and Myosin Studies

Cited by 656

CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction

McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 287

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

Jackson, A. M., Dewan, P., Anand, I. S., Bělohlávek, J., Bengtsson, O., de Boer, R. A., Böhm, M., Boulton, D. W., Chopra, V. K., DeMets, D. L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 175

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis

O’Meara, E., McDonald, M., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Grzeslo, A., Heckman, G. A., Howlett, J. G., Koshman, S. L., et al. (2020) · Canadian Journal of Cardiology

Heart Failure Treatment and ManagementAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 122

Care Gaps in Adherence to Heart Failure Guidelines

Jarjour, M., Henri, C., de Denus, S., Fortier, A., Bouabdallaoui, N., Nigam, A., O’Meara, E., Ahnadi, C., White, M., Garceau, P., et al. (2020) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiac pacing and defibrillation studies

Cited by 105

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 95

Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 44

Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF

Dewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 41